CYP2C-catalyzed delta(9)-tetrahydrocannabinol metabolism: Kinetics, pharmacogenetics and interaction with phenytoin

Biochemical Pharmacology

Volumn 70, Issue 7, 2005, Pages 1096-1103

  Bland, Tina M ^a   Haining, Robert L ^a   Tracy, Timothy S ^b   Callery, Patrick S ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

CYP2C; Drug interaction; Drug metabolism; Pharmacogenetics; Phenytoin; Tetrahydrocannabinol

Indexed keywords

CYTOCHROME P450 2C9; DRONABINOL; PHENYTOIN; CYTOCHROME P 450 CYP2C SUBFAMILY; CYTOCHROME P-450 CYP2C SUBFAMILY; CYTOCHROME P450; TETRAHYDROCANNABINOL;

ARTICLE; BINDING AFFINITY; CALCULATION; CATALYSIS; CONTROLLED STUDY; DRUG METABOLISM; HUMAN; HUMAN CELL; HYDROXYLATION; KINETICS; LIVER MICROSOME; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; DRUG ANTAGONISM; DRUG INTERACTION; ENZYME SPECIFICITY; ENZYMOLOGY; METABOLISM; PHARMACOGENETICS;

CATALYSIS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; HYDROXYLATION; MICROSOMES, LIVER; PHARMACOGENETICS; PHENYTOIN; SUBSTRATE SPECIFICITY; TETRAHYDROCANNABINOL;

EID: 24344435153     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2005.07.007     Document Type: Article

References (34)

1. Y. Gaoni, and R. Mechoulam Isolation, structure and partial synthesis of an active constituent of hashish J Am Chem Soc 86 1964 1646 1647
2. M.E. Wall, B.M. Sadler, D. Brine, H. Taylor, and M. Perez-Reyes Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women Clin Pharmacol Ther 34 1983 352 363
3. L.M. Bornheim, J.M. Lasker, and J.L. Raucy Human hepatic microsomal metabolism of delta 1-tetrahydrocannabinol Drug Metab Dispos 20 1992 241 246
4. A.E. Rettie, L.C. Wienkers, F.J. Gonzalez, W.F. Trager, and K.R. Korzekwa Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9 Pharmacogenetics 4 1994 39 42
5. D.J. Steward, R.L. Haining, K.R. Henne, G. Davis, T.H. Rushmore, and W.F. Trager Genetic association between sensitivity to warfarin and expression of CYP2C9*3 Pharmacogenetics 7 1997 361 367
6. R.S. Kidd, T.B. Curry, S. Gallagher, T. Edeki, J. Blaisdell, and J.A. Goldstein Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin Pharmacogenetics 11 2001 803 808
7. J. Kirchheiner, J. Brockmoller, I. Meineke, S. Bauer, W. Rohde, and C. Meisel Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers Clin Pharmacol Ther 71 2002 286 296
8. T.S. Tracy, J.M. Hutzler, R.L. Haining, A.E. Rettie, M.A. Hummel, and L.J. Dickmann Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles Drug Metab Dispos 30 2002 385 390
9. L.E. Hollister, and H.K. Gillespie Action of delta-9- tetrahydrocannabinol. An approach to the active metabolite hypothesis Clin Pharmacol Ther 18 1975 714 719
10. T.E. Wilens, J. Biederman, and T.J. Spencer Case study: adverse effects of smoking marijuana while receiving tricyclic antidepressants J Am Acad Child Adolesc Psychiatry 36 1997 45 48
11. A.L. Stoll, J.O. Cole, and S.E. Lukas A case of mania as a result of fluoxetine-marijuana interaction J Clin Psychiatry 52 1991 280 281
12. O.H. Lowry, N.J. Rosebrough, A.L. Farr, and R.J. Randall Protein measurement with the Folin phenol reagent J Biol Chem 193 1951 265 275
13. R.L. Haining, A.P. Hunter, M.E. Veronese, W.F. Trager, and A.E. Rettie Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms Arch Biochem Biophys 333 1996 447 458
14. T. Omura, and R. Sato The carbon monoxide-binding pigment of liver microsomes. II. Solubilzation, purification, and properties J Biol Chem 239 1964 2379 2385
15. T.D. Bjornsson, J.T. Callaghan, H.J. Einolf, V. Fischer, L. Gan, and S. Grimm The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective Drug Metab Dispos 31 2003 815 832
16. K.H. Liu, M.J. Kim, W.M. Jung, W. Kang, I.J. Cha, and J.G. Shin Lansoprazole enantiomer activates human liver microsomal CYP2C9 catalytic activity in a stereospecific and substrate-specific manner Drug Metab Dispos 33 2005 209 213
17. W. Zhang, Y. Ramamoorthy, T. Kilicarslan, H. Nolte, R.F. Tyndale, and E.M. Sellers Inhibition of cytochromes P450 by antifungal imidazole derivatives Drug Metab Dispos 30 2002 314 318
18. J.M. Hutzler, M.J. Hauer, and T.S. Tracy Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model Drug Metab Dispos 29 2001 1029 1034
19. M. Bajpai, L.K. Roskos, D.D. Shen, and R.H. Levy Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite Drug Metab Dispos 24 1996 1401 1403
20. L.S. Kaminsky, S.M. de Morais, M.B. Faletto, D.A. Dunbar, and J.A. Goldstein Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe Mol Pharmacol 43 1993 234 239
21. A.E. Rettie, K.R. Korzekwa, K.L. Kunze, R.F. Lawrence, A.C. Eddy, and T. Aoyama Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions Chem Res Toxicol 5 1992 54 59
22. L.J. Dickmann, A.E. Rettie, M.B. Kneller, R.B. Kim, A.J. Wood, and C.M. Stein Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans Mol Pharmacol 60 2001 382 387
23. E. Garcia-Martin, C. Martinez, J.M. Ladero, F.J. Gamito, and J.A. Agundez High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population Eur J Clin Pharmacol 57 2001 47 49
24. R. Loebstein, H. Yonath, D. Peleg, S. Almog, M. Rotenberg, and A. Lubetsky Interindividual variability in sensitivity to warfarin-nature or nurture? Clin Pharmacol Ther 70 2001 159 164
25. M.G. Scordo, E. Aklillu, U. Yasar, M.L. Dahl, E. Spina, and M. Ingelman-Sundberg Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population Br J Clin Pharmacol 52 2001 447 450
26. M.J. Stubbins, L.W. Harries, G. Smith, M.H. Tarbit, and C.R. Wolf Genetic analysis of the human cytochrome P450 CYP2C9 locus Pharmacogenetics 6 1996 429 439
27. T.H. Sullivan-Klose, B.I. Ghanayem, D.A. Bell, Z.Y. Zhang, L.S. Kaminsky, and G.M. Shenfield The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism Pharmacogenetics 6 1996 341 349
28. U. Yasar, E. Eliasson, M.L. Dahl, I. Johansson, M. Ingelman-Sundberg, and F. Sjoqvist Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population Biochem Biophys Res Commun 254 1999 628 631
29. K.R. Korzekwa, N. Krishnamachary, M. Shou, A. Ogai, R.A. Parise, and A.E. Rettie Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites Biochemistry 37 1998 4137 4147
30. A.C. Egnell, C. Eriksson, N. Albertson, B. Houston, and S. Boyer Generation and evaluation of a CYP2C9 heteroactivation pharmacophore J Pharmacol Exp Ther 307 2003 878 887
31. R.W. Wang, D.J. Newton, N. Liu, W.M. Atkins, and AY.H. Lu Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent Drug Metab Dispos 28 2000 360 366
32. A.C. Egnell, J.B. Houston, and C.S. Boyer Predictive models of CYP3A4 heteroactivation: in vitro-in vivo scaling and pharmacophore modeling J Pharmacol Exp Ther 312 2005 926 937
33. T.S. Maurer, D.B. DeBartolo, D.A. Tess, and D.O. Scott Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice Drug Metab Dispos 33 2005 175 181
34. C.A. Hunt, and R.T. Jones Tolerance and disposition of tetrahydrocannabinol in man J Pharmacol Exp Ther 215 1980 35 44